The latest IRDiRC paper, “Drug Repurposing for Rare: Progress and Opportunities for the Rare Disease Community” has been published in […]
Read More
New Publication: Making Rare Disease Research Attractive to Companies by IRDiRC Chrysalis Task Force
Accessible at https://doi.org/10.1177/26330040231188979, the Chrysalis Task Force identified key financial and non-financial factors that make rare disease research and development […]
Read More
IRDiRC’s Diagnostic Scientific Committee (DSC) plays a critical role in identifying and addressing current and future bottlenecks to rare disease gene […]
Read More
The Interdisciplinary Scientific Committee (ISC) is a multi-stakeholder, multi-disciplinary group of experts in rare diseases medical research with a strong […]
Read More
IRDiRC launches the Call for Members for the four new Task Forces of the 2023 Roadmap. Check out the newly approved Task […]
Read More
IRDiRC’s Therapies Scientific Committee (TSC) would like to broaden the committee membership, to represent the worldwide rare diseases therapies community in […]
Read More
The International Rare Diseases Research Consortium (IRDiRC) and the European Joint Programme on Rare Diseases (EJP RD) are jointly organizing […]
Read More
IRDiRC is delighted to share the release of Connecting the dots: Embedding progress on rare disease into healthcare, an Economist […]
Read More
IRDiRC is proud to announce that, as one of the outcomes of the MedTech for Rare Diseases Working Group led […]
Read More
The International Rare Diseases Research Consortium (IRDiRC) is proud to announce that the commentary on 10 years of progress and […]
Read More